Document is current
Any future updates will be listed below
-
Authors
Altamura, Claudia https://orcid.org/0000-0002-5934-5535
Brunelli, Nicoletta https://orcid.org/0000-0002-8590-9015
Marcosano, Marilena
Aurilia, Cinzia https://orcid.org/0000-0002-2658-2243
Egeo, Gabriella https://orcid.org/0000-0003-3068-4522
Lovati, Carlo https://orcid.org/0000-0002-4107-6189
Favoni, Valentina https://orcid.org/0000-0001-5335-2438
Perrotta, Armando https://orcid.org/0000-0002-1339-426X
Maestrini, Ilaria https://orcid.org/0000-0003-4996-7506
Schiano Di Cola, Francesca https://orcid.org/0000-0003-4365-8278
d’Onofrio, Florindo
Finocchi, Cinzia https://orcid.org/0000-0003-4385-1203
Bertuzzo, Davide
Bono, Francesco https://orcid.org/0000-0002-4650-6635
Ranieri, Angelo https://orcid.org/0000-0001-5450-1909
Albanese, Maria https://orcid.org/0000-0002-5113-2017
Messina, Roberta
Doretti, Alberto https://orcid.org/0000-0002-1015-7365
Di Piero, Vittorio https://orcid.org/0000-0002-2631-7562
Cevoli, Sabina https://orcid.org/0000-0003-4668-4295
Barbanti, Piero https://orcid.org/0000-0002-5670-3755
Vernieri, Fabrizio https://orcid.org/0000-0002-9594-9336
,
Costa, Carmelina Maria
Fofi, Luisa
Rao, Renata
d’Onofrio, Luigi
Spitalieri, Daniele
Aguggia, Marco
Bombardieri, Fabio
Colombo, Bruno
Filippi, Massimo
Messina, Stefano
Demirtzidis, Gianluca
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04803513 at ClinicalTrials.govDocuments that mention this clinical trial
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
https://doi.org/10.1007/s00415-022-11226-4
- License Information
-
More Information
Article History
Received: 20 March 2022
Revised: 10 June 2022
Accepted: 10 June 2022
First Online: 28 June 2022
Declarations
:
: Maria Albanese received honoraria or travel grants from Novartis, Teva, Merck Serono; Claudia Altamura received travel grants and honoraria from Novartis, Eli Lilly, Lusofarmaco, Laborest, Allergan, Almirall; Cinzia Aurilia received travel grants and honoraria from FB-Health, Lusofarmaco, Almirall, Eli-Lilly Novartis and Teva; Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Bayer, ElectroCore, Eli-Lilly, GSK, Lusofarmaco, MSD, Novartis, Stx-Med, Teva, Visufarma, Zambon; Francesco Bono received honoraria as a speaker or for participating in advisory boards from Teva, Novartis, Ipsen; Sabina Cevoli received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, Amgen and Lundbeck; Vittorio Di Piero received grants and honoraria by Bayer, Biogen, Lilly, TEVA and Novartis; Florindo d’Onofrio received grants and honoraria from Lilly, Teva, Novartis, Neopharmed; Alberto Doretti received grants and honoraria from Novartis, Eli Lilly; Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta and Ecupharma; Valentina Favoni received honoraria as speaker or for participating in advisory boards from Ely-Lilly, Novartis and Teva; Cinzia Finocchi received grants and honoraria from Novartis, Eli Lilly, AIM group; Carlo Lovati received grants from Novartis and Lilly. Florindo d’Onofrio received grants and honoraria from Lilly, Teva, Novartis, Neopharmed; Ilaria Maestrini received honoraria from Eli Lilly. Roberta Messina received honoraria as speaker from Novartis, Eli Lilly, and Teva. Armando Perrotta travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Eli-Lilly, Novartis, and Teva; Angelo Ranieri received speaker honoraria from Teva, Lilly; Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Amgen, Angelini, Eli-Lilly, Lundbeck, Novartis, and Teva; Nicoletta Brunelli, Marilena Marcosano and Francesca Schiano Di Cola, Davide Bertuzzo have nothing to disclose.
: The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki. All patients provided written informed consent. The study was approved by the Campus Bio-Medico University Ethical Committee n.30/20, mutually recognized by the other local ethical committees, and registered at the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) and at ClinicalTrials.gov NCT04803513.
